Success Metrics

Clinical Success Rate

87.5%

Based on 7 completed trials

Completion Rate

88%(7/8)

Active Trials

2(15%)

Results Posted

14%(1 trials)

Terminated

1(8%)

Phase Distribution

Ph phase_1

38%

Ph not_applicable

Ph phase_3

15%

Ph phase_2

23%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution11 total trials

Phase 1Safety & dosage

5(45.5%)

Phase 2Efficacy & side effects

3(27.3%)

Phase 3Large-scale testing

2(18.2%)

N/ANon-phased studies

1(9.1%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

87.5%

7 of 8 finished

Non-Completion Rate

12.5%

1 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Active(2)

Completed(7)

Terminated(1)

Other(3)

Detailed Status

Completed7

unknown3

Recruiting2

Terminated1

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

87.5%

Most Advanced

Phase 3

Trials by Phase

Phase 15 (45.5%)

Phase 23 (27.3%)

Phase 32 (18.2%)

N/A1 (9.1%)

Trials by Status

completed754%

recruiting215%

unknown323%

terminated18%

Recent Activity

2 active trials

Showing 5 of 13

completedphase_1

Drug Repurposing - Statins as Microbiota Modulating Agents in Ulcerative Colitis

NCT04883840

recruitingnot_applicable

Protective Effect of Statin Against Negative Cardiovascular Remodeling and Organ Dysfunction After Acute Aortic Syndrome Surgery (PANDA III)

NCT04699279

View all 13 trials

Clinical Trials (13)

Showing 13 of 13 trials

NCT06981299Phase 1

A Phase 1 Study of PROT-001.

Completed

NCT05064488Phase 1

Drug-Drug Interaction Study of Evobrutinib and Transporter Substrates

Completed

NCT04903223Phase 1

Liver Adiposity Effects on Pediatric Statin

Recruiting

NCT04883840Phase 2

Drug Repurposing - Statins as Microbiota Modulating Agents in Ulcerative Colitis

Terminated

NCT04699279Not Applicable

Protective Effect of Statin Against Negative Cardiovascular Remodeling and Organ Dysfunction After Acute Aortic Syndrome Surgery (PANDA III)

Recruiting

NCT04921657

Genome-wide Analysis of Lipid-lowering Efficacy and Drug Level of Simvastatin and Rosuvastatin

Completed

NCT04817904Phase 2

Evaluation of the Effect of Rosuvastatin on Cisplatin-induced Nephrotoxicity and Ototoxicity

Unknown

NCT04504851Phase 2

Rosuvastatin Evaluation as a Tuberculosis Treatment Adjunct

Unknown

NCT02518503

High Potency Statins and the Risk of Diabetes

Completed

NCT02445352Phase 3

Efficacy/Safety of DP-R207 Tablet Versus CRESTOR Tablet in Patients With Primary Hypercholesterolemia

Completed

NCT02087540Phase 3

Efficacy and Safety of Telmisartan/Rosuvastatin Co-administration in Hypertensive Patients With Hyperlipidemia

Unknown

NCT02026817Phase 1

Comparison of PK After Administration of HCP1201 and Co-administration of Metformin SR 750mg and Rosuvastatin 10mg

Completed

NCT02011633Phase 1

Comparison of PK After Administration of HCP1201 and Co-administration of Metformin SR 500mg and Rosuvastatin 10mg

Completed

All 13 trials loaded

Drug Details

Intervention Type: DRUG
Total Trials: 13